Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The following transaction prices are noted:
- Ordinary Shares: GBP 14.61 per share
- Ordinary Share ADRs: $51.96 per ADR
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADRs for various executives following the notional re-investment of the dividend paid to shareholders on January 5, 2006. Specific increases include:
- Mr. R Bondy: 1,101.210 Ordinary shares
- Dr. J P Garnier: 2,855.029 ADRs
- Mr. D Stout: 1,056.361 ADRs
- Mr. A Witty: 970.047 Ordinary shares
- Dr. T Yamada: 856.509 ADRs
- Other participants: Various amounts of Ordinary shares and ADRs as listed in the filing.
Guidance, Outlook, and Risks
The filing does not contain guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The notification complies with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the vesting schedule and conditions for the Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares and ADRs held by each executive post-transaction to assess concentration of ownership.
- Review the dividend payment date of January 5, 2006, to correlate with the re-investment transaction.